149 related articles for article (PubMed ID: 25835357)
1. Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
Jorda R; Schütznerová E; Cankař P; Brychtová V; Navrátilová J; Kryštof V
Bioorg Med Chem; 2015 May; 23(9):1975-81. PubMed ID: 25835357
[TBL] [Abstract][Full Text] [Related]
2. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
[TBL] [Abstract][Full Text] [Related]
5. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors.
Sun J; Lv XH; Qiu HY; Wang YT; Du QR; Li DD; Yang YH; Zhu HL
Eur J Med Chem; 2013 Oct; 68():1-9. PubMed ID: 23933045
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.
Lin R; Chiu G; Yu Y; Connolly PJ; Li S; Lu Y; Adams M; Fuentes-Pesquera AR; Emanuel SL; Greenberger LM
Bioorg Med Chem Lett; 2007 Aug; 17(16):4557-61. PubMed ID: 17574416
[TBL] [Abstract][Full Text] [Related]
10. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
[TBL] [Abstract][Full Text] [Related]
11. RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.
Lamie PF
Bioorg Med Chem Lett; 2016 Jul; 26(13):3093-3097. PubMed ID: 27189674
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
[TBL] [Abstract][Full Text] [Related]
13. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V⁶⁰⁰E) inhibitors.
Zhao MY; Yin Y; Yu XW; Sangani CB; Wang SF; Lu AM; Yang LF; Lv PC; Jiang MG; Zhu HL
Bioorg Med Chem; 2015 Jan; 23(1):46-54. PubMed ID: 25496804
[TBL] [Abstract][Full Text] [Related]
17. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.
Trova MP; Barnes KD; Barford C; Benanti T; Bielaska M; Burry L; Lehman JM; Murphy C; O'Grady H; Peace D; Salamone S; Smith J; Snider P; Toporowski J; Tregay S; Wilson A; Wyle M; Zheng X; Friedrich TD
Bioorg Med Chem Lett; 2009 Dec; 19(23):6608-12. PubMed ID: 19846305
[TBL] [Abstract][Full Text] [Related]
18. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, antitumor activity and CDK1 inhibiton of new thiazole nortopsentin analogues.
Parrino B; Attanzio A; Spanò V; Cascioferro S; Montalbano A; Barraja P; Tesoriere L; Diana P; Cirrincione G; Carbone A
Eur J Med Chem; 2017 Sep; 138():371-383. PubMed ID: 28688277
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.
Zhao H; Hu X; Cao K; Zhang Y; Zhao K; Tang C; Feng B
Eur J Med Chem; 2018 Sep; 157():935-945. PubMed ID: 30165341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
